Rahma Elmahdi

Dr. Rahma Elmahdi

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RERahma Elmahdi
Rahma Elmahdi
CLCamilla E. Lemser
Camilla E. Lemser
STSandra B. Thomsen
Sandra B. Thomsen
KAKristine H. Allin
Kristine H. Allin
MAManasi Agrawal
Manasi Agrawal
TJTine Jess
Tine Jess
The hallmarks of inflammatory bowel disease (IBD), a chronic immune-mediated inflammatory disease of the gastrointestinal tract, are progressive intestinal injury and systemic inflammation, which can lead to complications such as cancer. Inflammatory bowel disease is associated with an increased risk of several types of cancer, including colon, small bowel, and upper gastrointestinal tract cancers.1 In contrast to the risk of cancer among adult patients with IBD, the risk of cancer among patients with pediatric-onset IBD is not well investigated, to our knowledge. Pediatric patients with IBD may have longer durations of exposure to the chronic inflammatory state and thereby a higher risk of cancer.2 Furthermore, among children, the incidence of IBD and the risk of cancer have increased in recent years.3,4

27 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AEAnthony Ebert
Anthony Ebert
SHShania Harper
Shania Harper
MVMarie V. Vestergaard
Marie V. Vestergaard
WMWayne Mitchell
Wayne Mitchell
TJTine Jess
Tine Jess
RERahma Elmahdi
Rahma Elmahdi
Infectious mononucleosis (IM) is suspected to be associated with inflammatory bowel disease (IBD) development. Using a Danish nationwide cohort of people developing severe IM and their age-, sex-, and socioeconomic (SES) index-matched counterparts, we investigated the subsequent risk of IBD, Crohn’s disease (CD), or ulcerative colitis (UC) development from 1977 to 2021. Among 39,684 severe IM patients we find a sex-, age-, and SES index-adjusted HR for IBD of 1.35 (95% CI: 1.22–1.49). This significantly increased risk was seen for both CD (HR: 1.56; 95% CI: 1.34–1.83) and to a lesser extent UC (HR: 1.23; 95% CI: 1.08–1.40) and remains following negative control matching with a cohort diagnosed with Chlamydia trachomatis infection (HR: 1.39; 95% CI: 1.01–1.91). Those with severe IM at 0–9 years had a particularly increased risk for CD (HR: 1.77; 95% CI: 1.26–2.49). Here we show an increased risk for IBD diagnosis following IM hospitalisation, indicating an association between severe EBV disease and later IBD development. Further exploration of the potential factors contributing to IBD susceptibility following EBV disease is warranted.

15 June 2022 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
SMSimran Mann
Simran Mann
TJTine Jess
Tine Jess
KAKristine Allin
Kristine Allin
RERahma Elmahdi
Rahma Elmahdi
INTRODUCTION: There is increased risk of several malignancies in inflammatory bowel disease (IBD). However, evidence regarding risk of cervical cancer in IBD is conflicting. We aimed to investigate the risk of cervical cancer in IBD by undertaking a systematic review and meta-analysis of unselected, population-based studies. METHODS: MEDLINE, EMBASE, and Cochrane Library were searched using Medical Subject Heading terms, and 2 reviewers independently screened results. Pooled hazard ratios (HRs) were calculated using random effects model meta-analysis for risk of cervical cancer in IBD. Subgroup meta-analysis was undertaken to assess risk of cervical cancer by IBD subtype (Crohn's disease and ulcerative colitis), treatment exposure, and grade of lesion. RESULTS: We screened 1,393 articles to identify 5 population-based studies, including 74,310 patients with IBD and 2,029,087 reference patients, across 5 different countries. Pooled random effects model meta-analysis of these studies did not show statistically significant increased risk for cervical cancer in IBD compared with reference populations (HR: 1.24; 95% confidence interval [CI]: 0.94–1.63). Meta-analysis by grade of lesion showed increased risk of low-grade cervical lesions (HR: 1.15; 95% CI: 1.04–1.28). Meta-analysis by disease subtype indicated no statistically significant increased risk in Crohn's disease (HR: 1.36; 95% CI: 0.83–2.23) or ulcerative colitis (HR: 0.95; 95% CI: 0.72–1.25) or in patients treated with antitumor necrosis factor (HR: 1.19; 95% CI: 0.64–2.21) or thiopurines (HR: 0.96; 95% CI: 0.60–1.50). DISCUSSION: This meta-analysis of high-quality, unselected population-based studies shows no statistically significant increased risk of cervical cancer in patients with IBD. There is, however, increased risk of low-grade cervical lesions compared with the general population.

19 November 2024 in Journal of Virology
Verified
Journal Article
Closed access
JSJed Valentiner Shrewsbury
Jed Valentiner Shrewsbury
EVEvangelin Shaloom Vitus
Evangelin Shaloom Vitus
AKAdam Leslie Koziol
Adam Leslie Koziol
ANAnna Nenarokova
Anna Nenarokova
TJTine Jess
Tine Jess
RERahma Elmahdi
Rahma Elmahdi
Phage immunoprecipitation sequencing (PhIP-Seq) is a high-throughput platform that uses programmable phage display for serology. VirScan, a specific PhIP-Seq library encoding viral peptides from all known human viruses, enables comprehensive quantification of past viral exposures. We review its use in immune-mediated diseases (IMDs), highlighting its utility in identifying viral exposures in the context of IMD development. Finally, we evaluate its potential for precision medicine by integrating it with other large-scale omics data sets.

1 October 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VKVictoria S. Kjærgaard
Victoria S. Kjærgaard
CJCamilla B. Jensen
Camilla B. Jensen
RERahma Elmahdi
Rahma Elmahdi
JBJohan Burisch
Johan Burisch
KAKristine H. Allin
Kristine H. Allin
TJTine Jess
Tine Jess

11 August 2022 in Gastro Hep Advances
Verified
Journal Article
Open access
RERahma Elmahdi
Rahma Elmahdi
GKGursimran S. Kochhar
Gursimran S. Kochhar
AIAske T. Iversen
Aske T. Iversen
KAKristine H. Allin
Kristine H. Allin
PDParambir S. Dulai
Parambir S. Dulai
TJTine Jess
Tine Jess
Human immunodeficiency virus (HIV) infection is associated with several immune-mediated disorders. However, the risk of inflammatory bowel disease (IBD) in people living with HIV (PLWH) remains unclear. We aimed to assess the risk of IBD among PLWH using a nationwide, population-based Danish cohort and to validate findings in a large American insurance-based database. Using Danish registries (1983–2018), we identified 8995 PLWH and age- and sex-matched them to 449,750 HIV-negative individuals. Cox regression analysis was undertaken to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for IBD diagnosis. Results were stratified by sex, age, and year of HIV diagnosis. Using an American insurance-based cohort, Explorys (1999–2018), we assessed the prevalence odds ratio (OR) and 95% CI of IBD diagnosis in PLWH compared with HIV-negative individuals. IBD diagnosis among PLWH in Denmark was increased (HR: 2.25, 95% CI: 1.78–2.83) compared with matched HIV-negative individuals. This was seen for both Crohn’s disease (HR: 2.25, 95% CI: 1.47–3.44) and ulcerative colitis (HR: 2.24, 95% CI: 1.70–2.96) and in male (HR: 2.75, 95% CI: 2.15–3.52) but not female (HR: 0.93, 95% CI: 0.48–1.79) PLWH. Explorys analysis also showed an increased odds of IBD diagnoses among PLWH (OR: 1.41; 95% CI: 1.35–1.49). This study finds an increased risk of IBD diagnosis among PLWH in both a Danish and US cohort, highlighting a need to consider IBD in PLWH with new-onset gastrointestinal symptoms. Further research into the role of antiretroviral therapy in this relationship is required.